Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 70

Related Articles by Review for PubMed (Select 22785351)

1.

The ERBB network: at last, cancer therapy meets systems biology.

Yarden Y, Pines G.

Nat Rev Cancer. 2012 Jul 12;12(8):553-63. doi: 10.1038/nrc3309.

PMID:
22785351
2.

Small molecule inhibitors of the class 1 receptor tyrosine kinase family.

Cockerill GS, Lackey KE.

Curr Top Med Chem. 2002 Sep;2(9):1001-10. Review.

PMID:
12171567
3.

Biological significance of c-erbB family oncogenes in head and neck cancer.

Rogers SJ, Harrington KJ, Rhys-Evans P, O-Charoenrat P, Eccles SA.

Cancer Metastasis Rev. 2005 Jan;24(1):47-69. Review.

PMID:
15785872
4.

Targeting ErbB receptors in high-grade glioma.

Berezowska S, Schlegel J.

Curr Pharm Des. 2011;17(23):2468-87. Review.

PMID:
21827413
5.

ERBB oncogene proteins as targets for monoclonal antibodies.

Polanovski OL, Lebedenko EN, Deyev SM.

Biochemistry (Mosc). 2012 Mar;77(3):227-45. doi: 10.1134/S0006297912030029. Review.

PMID:
22803941
6.

Stratified medicine for cancer therapy.

Shaw EC, Johnson PW.

Drug Discov Today. 2012 Mar;17(5-6):261-8. Review.

PMID:
22493785
7.

EGF-ERBB signalling: towards the systems level.

Citri A, Yarden Y.

Nat Rev Mol Cell Biol. 2006 Jul;7(7):505-16. Review.

PMID:
16829981
8.

Targeting ERBB receptors in cancer.

Hynes NE.

Recent Results Cancer Res. 2007;172:45-57. Review. No abstract available.

PMID:
17607935
9.

ErbB receptor tyrosine kinase inhibitors as therapeutic agents.

Anderson NG, Ahmad T.

Front Biosci. 2002 Sep 1;7:d1926-40. Review.

PMID:
12161338
10.

ERBB receptors and cancer: the complexity of targeted inhibitors.

Hynes NE, Lane HA.

Nat Rev Cancer. 2005 May;5(5):341-54. Review. Erratum in: Nat Rev Cancer. 2005 Jul;5(7):580.

PMID:
15864276
11.

Receptor tyrosine kinases as targets for anticancer drugs.

Zwick E, Bange J, Ullrich A.

Trends Mol Med. 2002 Jan;8(1):17-23. Review.

PMID:
11796262
12.

Molecular determinants of response to RTK-targeting agents in nonsmall cell lung cancer.

Reinmuth N, Meister M, Muley T, Steins M, Kreuter M, Herth FJ, Hoffmann H, Dienemann H, Thomas M.

Int J Cancer. 2006 Aug 15;119(4):727-34. Review.

PMID:
16557579
13.

Smart drugs: tyrosine kinase inhibitors in cancer therapy.

Shawver LK, Slamon D, Ullrich A.

Cancer Cell. 2002 Mar;1(2):117-23. Review.

14.

Receptor tyrosine kinases: from biology to pathology.

Choura M, Rebaï A.

J Recept Signal Transduct Res. 2011 Dec;31(6):387-94. doi: 10.3109/10799893.2011.625425. Epub 2011 Oct 31. Review.

PMID:
22040163
15.

Receptor tyrosine kinases as target for anti-cancer therapy.

Brunelleschi S, Penengo L, Santoro MM, Gaudino G.

Curr Pharm Des. 2002;8(22):1959-72. Review.

PMID:
12171522
16.

Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers.

Sabbah M, Emami S, Redeuilh G, Julien S, Prévost G, Zimber A, Ouelaa R, Bracke M, De Wever O, Gespach C.

Drug Resist Updat. 2008 Aug-Oct;11(4-5):123-51. doi: 10.1016/j.drup.2008.07.001. Epub 2008 Aug 20. Review.

PMID:
18718806
17.

The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology.

Eccles SA.

Int J Dev Biol. 2011;55(7-9):685-96. doi: 10.1387/ijdb.113396se. Review.

18.

Tyrosine kinases as targets in cancer therapy - successes and failures.

Traxler P.

Expert Opin Ther Targets. 2003 Apr;7(2):215-34. Review.

PMID:
12667099
19.

Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis.

Porter AC, Vaillancourt RR.

Oncogene. 1998 Sep 17;17(11 Reviews):1343-52. Review.

20.

Network systems biology for targeted cancer therapies.

Zhou TT.

Chin J Cancer. 2012 Mar;31(3):134-41. doi: 10.5732/cjc.011.10282. Epub 2011 Dec 16. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk